![Philippe M. R. Guinot](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Philippe M. R. Guinot
Direktör/Styrelseledamot på
BioVex, Inc.
Profil
Philippe M.
R.
Guinot is currently a Director at BioVex, Inc. He previously held positions as Chairman at iTeos Therapeutics SA, Director at Diatos SA, Director at BioVex Group, Inc., Director at Xention Pharma Ltd., Director-Supervisory Board at PanGenetics BV, Director at Cytheris SA, Director at Amsterdam Molecular Therapeutics (AMT) Holding NV, Director at Era Biotech SA, Head-Drug Development Group at Beaufour Ipsen Pharma SAS, and Member-Supervisory Board at METabolic EXplorer SA. He was also a Senior Partner at Omnes Capital SAS from 2010 to 2011.
Aktiva positioner av Philippe M. R. Guinot
| Företag | Position | Start |
|---|---|---|
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology Develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases | Direktör/Styrelseledamot | 2009-05-15 |
Tidigare kända positioner av Philippe M. R. Guinot
| Företag | Position | Slut |
|---|---|---|
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology Engages in the discovery of immunomodulators for cancer therapy | Ordförande | 2018-06-27 |
Omnes Capital SAS /Venture/
 Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes-Venture is an active manager which aims to combine an industrial and strategic overview of their target sectors with operational support for investee companies and financial optimization of investments. The firm takes minority stakes in recently founded businesses with strong European and international potential, focusing on the electronics, software, telecoms, life sciences and web technology services sectors. Their investment policy draws on exclusive sources of deal flow, including the management team's personal networks and privileged links to incubator funds, start-up funds, research labs, fundraisers and Crdit Agricole group's proprietary networks. They typically invest between 2 and 10 million euros. Omnes-Venture partners with investee companies, taking seats on supervisory boards or the board of directors, while respecting investee management's independence. They contribute to the company's strategy and development opportunities, select candidates for key positions in investee companies, working to optimize their financial resources and source industrial and financial partnerships. | Privat kapitalinvesterare | 2011-04-01 |
BioVex Ltd.
 BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services Develops and commercializes biological treatments for cancer and infectious diseases | Direktör/Styrelseledamot | 2011-03-04 |
Diatos SA
 Diatos SA Pharmaceuticals: MajorHealth Technology Develops innovative therapies for the treatment of cancer | Direktör/Styrelseledamot | 2009-09-15 |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops and researches drugs | Direktör/Styrelseledamot | 2007-01-01 |
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
19
Första gradens relationer
13
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 13 |
|---|---|
Diatos SA
Diatos SA Pharmaceuticals: MajorHealth Technology Develops innovative therapies for the treatment of cancer | Health Technology |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology Develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases | Health Technology |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology Develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases | Health Technology |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops and researches drugs | Health Technology |
PanGenetics BV
 PanGenetics BV Miscellaneous Commercial ServicesCommercial Services Researches and develops antibody-based therapeutic products | Commercial Services |
Beaufour Ipsen Pharma SAS
 Beaufour Ipsen Pharma SAS Pharmaceuticals: OtherHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
BioVex Ltd.
BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services Develops and commercializes biological treatments for cancer and infectious diseases | Commercial Services |
Cytheris SA
 Cytheris SA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for immune modulation | Health Technology |
METabolic EXplorer SA
 METabolic EXplorer SA Chemicals: SpecialtyProcess Industries Engages in development, production and commercialization of bioprocesses, producing functional ingredients applied in cosmetics, animal nutrition & biopolymers | Process Industries |
Omnes Capital SAS /Venture/
Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes-Venture is an active manager which aims to combine an industrial and strategic overview of their target sectors with operational support for investee companies and financial optimization of investments. The firm takes minority stakes in recently founded businesses with strong European and international potential, focusing on the electronics, software, telecoms, life sciences and web technology services sectors. Their investment policy draws on exclusive sources of deal flow, including the management team's personal networks and privileged links to incubator funds, start-up funds, research labs, fundraisers and Crdit Agricole group's proprietary networks. They typically invest between 2 and 10 million euros. Omnes-Venture partners with investee companies, taking seats on supervisory boards or the board of directors, while respecting investee management's independence. They contribute to the company's strategy and development opportunities, select candidates for key positions in investee companies, working to optimize their financial resources and source industrial and financial partnerships. | Finance |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Specializes in human gene therapy for metabolic disorders and ocular diseases | Commercial Services |
Era Biotech SA
 Era Biotech SA Miscellaneous Commercial ServicesCommercial Services Develops cell-based biomanufacturing technologies | Commercial Services |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology Engages in the discovery of immunomodulators for cancer therapy | Health Technology |
